Fennec Pharmaceuticals Net Income Over Time
| FENC Stock | USD 7.85 0.14 1.82% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Fennec Pharmaceuticals Performance and Fennec Pharmaceuticals Correlation. Will Biotechnology sector continue expanding? Could Fennec diversify its offerings? Factors like these will boost the valuation of Fennec Pharmaceuticals. Market participants price Fennec higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Fennec Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.26) | Revenue Per Share | Quarterly Revenue Growth 0.787 | Return On Assets | Return On Equity |
Understanding Fennec Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects Fennec's accounting equity. The concept of intrinsic value—what Fennec Pharmaceuticals' is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Fennec Pharmaceuticals' price substantially above or below its fundamental value.
Please note, there is a significant difference between Fennec Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fennec Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Fennec Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Net Income Analysis
Compare Fennec Pharmaceuticals and related stocks such as Eupraxia Pharmaceuticals, Aardvark Therapeutics, and Cartesian Therapeutics Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AARD | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (7.2 M) | (20.6 M) | (18.5 M) | (19.5 M) |
| RNAC | (12.9 M) | (12.9 M) | (12.9 M) | (12.9 M) | (12.9 M) | (25.2 M) | (36.2 M) | (65.3 M) | (65.3 M) | (55.4 M) | (68.9 M) | (25.7 M) | 35.4 M | (219.7 M) | (77.4 M) | (69.7 M) | (73.2 M) |
| PRLD | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (27.6 M) | (56.9 M) | (110.8 M) | (107.3 M) | (121.8 M) | (127.2 M) | (114.5 M) | (120.2 M) |
| CRBU | (23.4 M) | (23.4 M) | (23.4 M) | (23.4 M) | (23.4 M) | (23.4 M) | (23.4 M) | (23.4 M) | (23.4 M) | (23.4 M) | (34.3 M) | (66.9 M) | (99.4 M) | (102.1 M) | (149.1 M) | (134.2 M) | (127.5 M) |
| AVTX | (10.5 M) | (10.5 M) | (10.5 M) | (13 M) | (16.1 M) | (10.5 M) | (16.5 M) | 11.9 M | (40.1 M) | (16.1 M) | (63.5 M) | (84.4 M) | (41.7 M) | (31.5 M) | (35.1 M) | (31.6 M) | (33.2 M) |
| ENTA | 7.9 M | 21.4 M | 9.6 M | 34.4 M | 79 M | 21.7 M | 17.7 M | 72 M | 46.4 M | (36.2 M) | (79 M) | (121.8 M) | (133.8 M) | (116 M) | (81.9 M) | (73.7 M) | (70 M) |
| BDTX | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (8.9 M) | (35.3 M) | (67.3 M) | (125.6 M) | (91.2 M) | (82.4 M) | (69.7 M) | (62.7 M) | (65.8 M) |
| NAUT | 626.6 M | 626.6 M | 626.6 M | 626.6 M | 626.6 M | 626.6 M | 626.6 M | 626.6 M | 626.6 M | (9.6 M) | (15.6 M) | (50.3 M) | (57.9 M) | (63.7 M) | (70.8 M) | (63.7 M) | (60.5 M) |
| OBIO | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (23 M) | (33.6 M) | (49.1 M) | (61 M) | (54.9 M) | (57.7 M) |
Fennec Pharmaceuticals and related stocks such as Eupraxia Pharmaceuticals, Aardvark Therapeutics, and Cartesian Therapeutics Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Fennec Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Fennec Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Fennec Pharmaceuticals | FENC |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 68 TW Alexander |
| Exchange | NASDAQ Exchange |
USD 7.85
Check out Fennec Pharmaceuticals Performance and Fennec Pharmaceuticals Correlation. For information on how to trade Fennec Stock refer to our How to Trade Fennec Stock guide.You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Fennec Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.